AVBP

ArriVent BioPharma, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001868279 Biotech & Drug Discovery

$21.00 +1.80 (+9.37%)

Oct 23 4:00 PM ET · prev $19.20

Market cap

$946.7M

Small cap

Consensus

Buy

94% Buy or better · 18 analysts

Median target

$21.00

0% · range $15.00–29.00

Next earnings

Nov 18

in 23 days · EPS est. −$1.07

1 year

+12.9%

from $18.60 · Oct 24

30 days

−30.2%

from $30.10

52-week range

$15.09–34.74

−40% from high · low Oct 6

Avg volume 20D

2.33M

Oct 6 spike 19.74M

Short interest

8.45M

≈17.1% of shares · −3.6%

Days to cover

11.3

at average volume

Insider net

-$13.0M

0 buyers · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 1 exit

SecBot read BULLISH 9 reports · 90 days

Balance 3 bearish · 4 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 6/9 ·Next Earnings date, Nov 18, 2026

Strongest BULLISH ArriVent announced that initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

InsidersBEARISH

1 insider sold $13.0M.
InstitutionsBULLISH

Q2 2026: 28 added (0 new), 7 trimmed or exited.
AnalystsBULLISH

17 of 18 rate it Buy or better. Median target $21.00 (0%).
EstimatesFALLING

Current-quarter EPS estimate −$0.996 → −$1.070 over 90 days. 2 up, 1 down in 30 days.
Short sellersSTEADY

Short interest −3.6% to 8.45M shares. 11.3 days to cover, ≈17.1% of shares.
TrendDOWNTREND

20% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exit

Fund	Move	Shares	Value
BlackRock, Inc.	ADD	3,250,396	$112.9M
D. E. Shaw & Co., Inc.	DOUBLED	872,011	$30.3M
AMERIPRISE FINANCIAL INC	DOUBLED	381,589	$13.3M
VANGUARD PORTFOLIO MANAGEMENT LLC	ADD	335,320	$11.6M
DIMENSIONAL FUND ADVISORS LP	ADD	211,509	$7.3M
MORGAN STANLEY	ADD	189,910	$6.6M
BANK OF AMERICA CORP /DE/	DOUBLED	174,866	$6.1M
NOMURA HOLDINGS INC	TRIM	154,617	$5.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts

Buy 94% rate it Buy or better

Strong Buy7Buy10Hold1Sell0Strong Sell0

12-month targets · 10 analysts

$21.00 $15.00 $21.00 $29.00

Price is inside the target range. Median implies 0%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 20, 2026	B. Riley Securities MAINTAIN	MAINTAIN	Buy
Oct 16, 2026	BTIG REITERATE	REITERATE	Buy
Oct 8, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Oct 7, 2026	Citigroup MAINTAIN	MAINTAIN	Buy
Oct 7, 2026	Jones Trading MAINTAIN	MAINTAIN	Buy
Oct 7, 2026	Truist Securities MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

bought · 0 insiders

$13.0M

sold · 1 insider

Date	Insider	Type	Value
Jun 18, 2026	Nolet Chris Director	AWARD	13,562 sh
Jun 18, 2026	Hohneker John Director	AWARD	13,562 sh
Jun 18, 2026	Peterson Kristine Director	AWARD	13,562 sh
Jun 18, 2026	Parsey Merdad Director	AWARD	13,562 sh
Feb 2, 2026	Lutzker Stuart President of R&D	AWARD	150,000 sh
Feb 2, 2026	Kastenmayer James Paul General Counsel	AWARD	130,000 sh
Feb 2, 2026	LaChapelle Robin Chief Operating Officer	AWARD	130,000 sh
Feb 2, 2026	Kung Winston Chief Financial Officer	AWARD	140,000 sh

Earnings setup

Estimates

Nov 18

reports in 23 days

−$1.07

EPS estimate, this quarter

−7%

estimate change, 90 days

2↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.996

90d

−$1.074

60d

−$1.074

30d

−$1.077

−$1.070

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$1.07	-$1.22–-$1.00	+0.3%	$0.00
Next Q	-$1.10	-$1.63–-$0.90	+3.2%	$0.00
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only